Who is sponsoring NCT02425800?

NCT02425800 is sponsored by Wake Forest University Health Sciences.

What drugs are being tested in NCT02425800?

Interventions in NCT02425800: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis.

What condition does NCT02425800 study?

NCT02425800 studies Benign Prostatic Hyperplasia, Prostate Carcinoma.

Is NCT02425800 still recruiting?

NCT02425800 is currently completed. Last updated 1 September 2021.

Last reviewed 2021-09-01 · How we verify

NCT02425800

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells

Completed Last updated 1 September 2021

What this trial tests

trial testing Cytology Specimen Collection Procedure in Benign Prostatic Hyperplasia in 43 participants. Completed in 3 August 2021.

Timeline

28 July 2015

Primary endpoint
5 November 2018

3 August 2021

Quick facts

Lead sponsor	Wake Forest University Health Sciences
Status	Completed
Study type	OBSERVATIONAL
Enrollment	43
Start date	28 July 2015
Primary completion	5 November 2018
Estimated completion	3 August 2021
Sites	2 locations across United States

Drugs / interventions tested

Cytology Specimen Collection Procedure
Laboratory Biomarker Analysis — full drug profile →

Conditions studied

Benign Prostatic Hyperplasia — all drugs for Benign Prostatic Hyperplasia →
Prostate Carcinoma — all drugs for Prostate Carcinoma →

Sponsor

Wake Forest University Health Sciences

Who can join

Eligibility, male only, with Benign Prostatic Hyperplasia or Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot research trial studies the use of a human prostate tissue model to maintain and study prostate cancer stem cells. A human prostate tissue model uses leftover tissue that was removed during surgery from patients with non-cancerous enlargement of the prostate (benign prostatic hyperplasia) and may create an environment similar to the natural environment of the human body. Prostate cancer stem cells are cells that cause cancer to grow. Using real tissue to create an environment to study stem cells may help doctors learn more about how they work and how they respond to treatments.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs.
Lee CH, Yu CC, Wang BY, Chang WW. · · 2016 · cited 128× · PMID 26527320 · DOI 10.18632/oncotarget.6261

Verify or expand the search:

Other trials of Cytology Specimen Collection Procedure

Trials testing the same drug.

NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04526587 — Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors · recruiting
NCT02514408 — Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer · withdrawn
NCT03057626 — Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma · active not recruiting

Other recruiting trials for Benign Prostatic Hyperplasia

Currently open trials in the same condition.

NCT07444385 — A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects · Phase 1 · recruiting
NCT07293442 — Pelvic Floor Muscle Exercise for Lower Urinary Tract Symptoms After Surgery for Benign Prostatic Hyperplasia. · NA · recruiting
NCT06657872 — Local Anesthesia With Schelin Catheter in Rezum Treatment: a Randomized Controlled Trial · NA · recruiting
NCT06852859 — Patient-reported Pain and Symptom Relief During Three Months After Surgery for Benign Prostatic Hyperplasia · recruiting
NCT06849258 — A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms · NA · recruiting

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02425800 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 1 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02425800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing